ArticleFrontiers in psychiatry2025
The effect of antidepressant medication use on HbA1c levels in type 2 diabetes.
Article in Frontiers in psychiatry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Chronic psychological symptoms such as anxiety and depression are known to negatively affect glycemic control in patients with type 2 diabetes (T2D). However, the impact of psychiatric treatment on glycemic outcomes remains underexplored. Objective: This study aimed to evaluate the effect of psychiatric treatment on HbA1c levels in T2D patients presenting with psychological symptoms. Methods: A total of 64 T2D patients with psychological complaints were retrospectively analyzed and divided into two groups based on psychiatric treatment status: 39 patients received antidepressant therapy, while 25 did not. Demographic data, comorbidities, and HbA1c levels before and after treatment or during follow-up were compared between groups. Statistical analyses were performed to assess differences in HbA1c changes. Results: There were no significant differences between groups regarding age, gender, or comorbid medical conditions (p>0.05). Patients receiving psychiatric treatment showed a significant reduction in HbA1c levels compared to those untreated (37.5% vs. 9.4% HbA1c decrease, p<0.001). Conversely, HbA1c levels increased in a higher proportion of untreated patients (28.1% vs. 15.6%). The reduction in HbA1c was more pronounced in individuals with baseline HbA1c levels above 8%. Patients treated with SSRIs, particularly sertraline and escitalopram, showed notable reductions in HbA1c levels. Conclusion: Our study suggests that antidepressant therapy in patients with depressive symptoms may contribute to reductions in HbA1c levels. This finding supports the notion that targeted treatment of depression can positively influence glycemic control. These results underscore the importance of integrating depression screening and management into T2D care strategies. Further longitudinal and large-scale studies are warranted to confirm these findings and clarify the mechanisms underlying the psychometabolic effects of antidepressants.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.